Abstract:Background: Emerging evidence suggests that female sex may be associated with increased risk of developing antiretroviral toxicities. Although the mechanisms of sex-related antiretroviral pharmacodynamic differences remain poorly understood and may be multifactorial, they appear to be mediated through a common pathway of pharmacokinetic variability between the sexes. Objective: This article reviews sex differences in the pharmacokinetics of the major classes of antiretroviral drugs currently approved for HIV treatment by the US Food and Drug Administration, identifies knowledge gaps, and provides recommendations for future research directions. Methods: To identify pertinent articles for this review, the MEDLINE database was searched from 1990 to June 2006 using the terms sex, gender, antiretroviral therapy, ART, HAART, pharmacokinetics, pharmacodynamics, NRTI, NNRTI, and protease inhibitors. Search results were restricted to English language and human studies. The reference lists of identified articles were also used, as well as abstracts from relevant conferences. In addition, individual antiretroviral drugs were searched by sex/gender or by pharmacokinetics. Results: Current evidence, though limited, does suggest the existence of a sex disparity in antiretroviral pharmacokinetics, and such disparity has been shown to have pharmacodynamic implications for some drugs. Sex-mediated intracellular pharmaco-enhancement was associated with superior antiviral activities for the zidovudine and lamivudine members of the nucleoside reverse transcriptase inhibitor class. There appears to be divergent opinions about whether sex is a significant determinant of either nevirapine or efavirenz plasma concentrations. For certain protease inhibitors (PIs) (eg, saquinavir [SQV] and indinavir [IDV]), clinically significant relationships between sex differences in plasma drug concentrations and clinical outcomes have been observed. There appears to be a trend toward higher drug exposure in women than in men when PIs are boosted with ritonavir (RTV). Nelfinavir, the only PI that is currently administered unboosted with RTV, does not exhibit a sex difference in its plasma concentrations. Unboosted amprenavir exposure was lower in women compared with men. Sex differences in the pharmacokinetics of SQV and IDV were observed only in the setting of RTV boosting. Conclusions: A common weakness in many studies addressing sex-based differences in the pharmacokinetics of antiretroviral drugs is the relatively small number of women participating. Many of these studies were retrospective in design, and some had limited pharmacokinetic parameters for comparison. Antiretroviral treatment trials should be designed with sufficient power (adequate female participation) to detect sex-based differences both in pharmacokinetics and in clinical response. Future studies should explore the molecular basis for sex-based differences in plasma drug concentrations and antiretroviral drug response. The roles of drug transporter proteins and cellular kinases, and the activities of metabolizing enzymes in mediating differential plasma and intracellular antiretroviral concentrations, should be further assessed.

Antiretroviral pharmacokinetic profile: a review of sex differences

Sex differences in pharmacokinetics predict adverse drug reactions in women

Gender Differences in HIV Drug Resistance Mutations and Virological Outcome

Are There Gender Differences in Starting Protease Inhibitors, HAART, and Disease Progression Despite Equal Access to Care?

Patterns and Rates of Viral Evolution in HIV-1 Subtype B Infected Females and Males

Individualized medicine: Sex, hormones, genetics, and adverse drug reactions

Sex Differences in Pharmacotherapy of Schizophrenia:Findings from National Survey 2012 on Use of Psychotropic Medications

Interaction of Sex and HIV Infection on Renal Impairment: Baseline Evidence from the CHART Cohort.

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Sex-specific considerations in cardiovascular drug therapy

A regulatory perspective on the role of drug interactions in antiretroviral drug development

Factors associated with sex differences in viral non‐suppression in the Swedish InfCareHIV cohort: An observational real‐world study

Rates of adverse events of antiretroviral therapy in women living with HIV/AIDS: a systematic review and meta-analysis

Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV

How Important Are Gender Differences in Pharmacokinetics?

The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy

Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis

Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts

Exploring gender differences in pharmacokinetics of central nervous system related medicines based on a systematic review approach

Sex differences in effectiveness and adverse effects of mood stabilizers and antipsychotics: A systematic review

The Association Between Poor Antiretroviral Adherence and Unsafe Sex: Differences by Gender and Sexual Orientation and Implications for Scale-up of Treatment as Prevention